

Nuclear Corp.) and reacting it with the adamantoyl chloride. The product obtained after work-up had a specific activity of 18 $\mu\text{Ci}/\text{mg}$.

Compounds. The 3-deazauridine used for antitumor evaluation in mice was purchased from the ICN Corp., Irvine, Calif.

Microbial Assays. The procedure used for these assays has been published previously.¹⁷

In Vitro Antitumor Assays. The *in vitro* antitumor assays were carried out by our micro technique whereby 0.5-ml aliquots of medium (RPMI 1630 + 10% calf serum) containing the analog are introduced into 16 \times 125 mm screw cap culture tubes, followed by 0.5-ml portions of the medium containing 3×10^5 L-1210 cells. The cultures are incubated at 37° for 40 hr, after which time the viable cells are counted by Trypan Blue exclusion. During this time, the cell number in the controls increases *ca.* eight- to ninefold with an average cell viability of 99%.

In Vivo Antitumor Assay. On day 0, DBA₂/Ha mice of the same age group (5–7 weeks) were separated into weight groups (17–19 g \pm 0.5 g). The ascites fluid from one or more mice (depending on the number of cells needed) inoculated ip with L-1210 cells 6–7 days prior to experiment was collected and the percentage of viable cells determined by Trypan Blue exclusion. The fluid was diluted with saline so that the 0.5-ml aliquot administered ip to each mouse contained 1×10^6 viable L-1210 cells. On day 1, the animals were randomized into the various test groups, and the deazapyrimidines were injected once daily for 6 consecutive days by the route indicated in Table II.

Biochemical Assays. To examine the cleavage of 4-*O*-adamantoyl-3-deazauridine, a total of 2 ml of packed L-1210 cells was collected from the intraperitoneal cavity of DBA₂/Ha mice. The cells were suspended in 10 ml of 0.05 *M* phosphate buffer, pH 7.5, and were disrupted by exposure for 1.5 min to a Bronson III sonifier. The cell debris was removed by centrifugation at 19,500g for 30 min, and a 4-ml aliquot of this extract was added to 5 ml of 0.05 *M* phosphate buffer, pH 7.5, containing 1×10^{-4} *M* 4-*O*-adamantoyl-³H-deazauridine (specific activity 18.0 $\mu\text{Ci}/\text{mg}$) and 1 ml of 0.1 *M* MgCl₂. (Such a large volume was used because of the relative insolubility of the adamantoyl derivative.) The mixture was incubated at 37°, and 1-ml aliquots were removed at stated intervals. They were immersed into boiling water for 2 min, the precipitates which formed were removed by centrifugation, the supernatant solutions were reduced in volume to 0.5 ml, and 0.1-ml portions were applied to Whatman No. 3 paper and were chromatographed together with authentic carriers in 1-butanol-H₂O (86:14) and a solvent prepared by dissolving 13.8 g of Na₂HPO₄·H₂O in 900 ml of H₂O and adjusting the pH to 6.8 with H₃PO₄. The volume was raised to 1 l. and 600 g of (NH₄)₂SO₄ and 20 ml of *n*-PrOH were added. In these two solvent systems the *R_F* of the ester 5 is 0.91 and 0.03 and that of 3-deazauridine (4) is 0.44 and 0.50, respectively. Strips 3 cm in width extending from the origin to the solvent front were cut from the chromatogram and were divided into 1-cm segments. Each segment was placed into a scintillation vial to which was added 20 ml of toluene containing 0.4% of 2,5-diphenyloxazole and 0.01% of 1,4-bis[2-(4-methyl-5-phenyloxazolyl)] benzene. Radioactivity was measured in a Packard TriCarb Model 3000 liquid scintillation counter. Control experiments were performed by incubating 5 in the same total volume of phosphate buffer, pH 7.5, containing 1 ml of 0.1 *M* MgCl₂ but no L-1210 cell extract.

Acknowledgments. The authors are grateful to Miss Rosemary Hromchak and Mr. Gary Bruns for their excellent technical assistance and thank Dr. E. Mihich for helpful discussions.

References


- J. Skoda, *Progr. Nucl. Acid Res. Mol. Biol.*, **2**, 197 (1963); C. E. Hoffmann in "Annual Reports in Medicinal Chemistry, 1967," C. K. Cain, Ed., Academic Press, New York, N. Y., 1968, p 120; G. M. Timmis and D. C. Williams, "Chemotherapy of Cancer," Butterworths, London, 1967.
- M. P. Mertes, J. Zielinski, and C. Pillar, *J. Med. Chem.*, **10**, 320 (1967).
- H. Pischel and G. Wagner, *Arch. Pharm. (Weinheim)*, **300**, 602 (1967), and references cited therein.
- M. J. Robins and B. L. Currie, *Chem. Commun.*, 1547 (1968); M. J. Robins, B. L. Currie, R. K. Robins, and A. Bloch, *Proc. Amer. Ass. Cancer Res.*, **10**, 73 (1969).
- (a) B. L. Currie, R. K. Robins and M. J. Robins, *J. Heterocycl. Chem.*, **7**, 323 (1970); (b) B. L. Currie, M. J. Robins, and R. K. Robins, *ibid.*, **8**, 221 (1971).
- G. L. Neil, P. F. Wiley, R. C. Manak, and T. E. Moxley, *Cancer Res.*, **30**, 1047 (1970).
- G. Errera, *Ber.*, **31**, 1682 (1898).
- J. Baumler, E. Sorkin, and H. Erlenmeyer, *Helv. Chim. Acta*, **34**, 496 (1951).
- R. J. Rousseau and R. K. Robins, *J. Heterocycl. Chem.*, **2**, 196 (1965).
- H. J. den Hertog and D. J. Buurman, *Recl. Trav. Chim. Pays-Bas*, **75**, 257 (1956).
- M. J. Robins, B. L. Currie, R. K. Robins, and A. D. Broom, *Can. J. Chem.*, **49**, 3067 (1971).
- A. Albert and J. N. Phillips, *J. Chem. Soc.*, 1294 (1956).
- J. Hine, "Physical Organic Chemistry," McGraw-Hill, New York, N. Y., 1956, pp 274–275.
- A. Albert, R. Goldacre, and J. N. Phillips, *J. Chem. Soc.*, 2240 (1948).
- M. C. Wang and A. Bloch, *Biochem. Pharmacol.*, **21**, 1063 (1972).
- A. Bloch, G. Dutschman, and G. Grindey, *Proc. Amer. Ass. Cancer Res.*, **13**, 19 (1972).
- A. Bloch and C. Coutsogeorgopoulos, *Biochemistry*, **5**, 3345 (1966).

Synthesis and Anticoccidial Activity of 3-Fluoro-5-chloro- and -bromo-2,6-dimethyl-4-pyridinol

Lowell D. Markley* and Michael K. Eckman


Ag-Organics Department, The Dow Chemical Company, Midland, Michigan 48640. Received August 18, 1972

3,5-Dichloro-2,6-dimethyl-4-pyridinol (clopidol, **1**) is the active component in the coccidiostat, COYDEN, sold by The Dow Chemical Co.^{1,2} Other 3,5-dihalo-2,6-dimethyl-4-pyridi-



nols including 3,5-dibromo, 3,5-diiodo, and 3-bromo-5-chloro have been synthesized and shown to have good anticoccidial activity.¹ Since many biologically active chemicals contain fluorine, it was of interest to synthesize several 3-fluoro-4-pyridinols and test them for possible anticoccidial activity.


The 3,5-dichloro-, 3,5-dibromo-, and 3,5-diiodo-2,6-dimethyl-4-pyridinols have been synthesized by halogenation of 2,6-dimethyl-4-pyridinol with chlorine,² bromine,³ and




iodine chloride,⁴ respectively. The synthesis of the fluoro derivatives has required the use of a more indirect approach since fluorination of 2,6-dimethyl-4-pyridinol did not seem feasible.

In 1965, Talik and coworkers⁵ reported synthesizing 4-chloro-3-fluoro-2,6-lutidine (**6**). From this compound, we were able to prepare our desired fluoro-substituted pyridinols. Talik's synthesis of **6** (Scheme I) was utilized with several modifications as given in the Experimental Section. Treatment of 3-fluoro-4-nitro-2,6-lutidine 1-oxide (**5**) with phosphorous trichloride gave 4-nitro-3-fluoro-2,6-lutidine (**7**), previously not reported by Talik, in addition to the desired 4-chloro-3-fluoro-2,6-lutidine (**6**). The two materials were readily separated *via* distillation.

Scheme I. Synthesis of 4-Chloro-3-fluoro-2,6-lutidine (6)




From 4-chloro-3-fluoro-2,6-lutidine (6) we synthesized the desired 3-chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10) and 3-bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11) via halo-



genation as outlined in Scheme II. Nucleophilic displacement of the 4-chloro group in 6 with 1 equiv of sodium methoxide took place readily at 130° giving 3-fluoro-4-methoxy-2,6-lutidine (8). Demethylation of 8 was attempted using three different reagents: boron tribromide, hydriodic acid, and sodium methoxide. A quantitative yield of demethylated product, 4-hydroxy-3-fluoro-2,6-lutidine (9), was obtained with excess sodium methoxide at 190°. From 9, the desired products, 10 and 11, were formed by chlorination and bromination, respectively.

Anticoccidial Activity. 3-Chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10) and 3-bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11) were tested against two strains of coccidiosis, *Eimeria necatrix* and *Eimeria acervulina*, using the method given in ref 1. As shown in Table I, both compounds showed activity equal to clopidol (1) against *E. necatrix* but little or no activity against *E. acervulina* at comparable concentrations.

Scheme II. Synthesis of 3,5-Dihalo-2,6-dimethyl-4-pyridinols (10 and 11)



Experimental Section

Melting points were determined with a Thomas-Hoover capillary melting point apparatus and are uncorrected. Ir spectra were recorded

Table I. Activity of Compounds 10 and 11 and Clopidol

No.	Per cent control of coccidiosis ^a			
	<i>E. necatrix</i>		<i>E. acervulina</i>	
	125 ppm	250 ppm	125 ppm	250 ppm
10	100	100	0	0
11	100	100	0	70
Clopidol	100	100	95	100

^aAnticoccidial index = % weight gain - (sum of the mean fecal and lesion scores). % coccidiosis control = (anticoccidial index of experimental group/anticoccidial index of uninoculated-unmedicated control)100.

on an Infracord spectrophotometer and nmr on a Varian Associates A-60 instrument (Me₄Si) and are in accord with proposed structures. Elemental analyses were obtained on new compounds 9, 10, and 11 and the results were within ±0.3% of the theoretical values of those elements indicated by symbols.

3-Fluoro-2,6-lutidine 1-Oxide (4). To 105 g (0.84 mol) of 3 dissolved in 500 ml of glacial AcOH was added 210 g (1.1 mol of peroxide) of 40% peracetic acid. The reaction mixture was heated at 75–78° for 12 hr and the solvent was then removed *in vacuo*. The liquid residue remaining was dissolved in 400 ml of CH₂Cl₂ and extracted with saturated NaHCO₃ and removal of solvent gave a quantitative yield of hydrated 4, mp ~15–20°, which was used without purification. Bellas and Suschitzky⁶ reported obtaining the pentahydrate, mp 53°.

4-Chloro-3-fluoro-2,6-lutidine (6) and 4-Nitro-3-fluoro-2,6-lutidine (7). To 114 g (0.615 mol) of 5 dissolved in 250 ml of CHCl₃ was added 250 ml (2.86 mol) of PCl₃. After heating the mixture for 3 hr at 65–70° and removal of solvent *in vacuo*, the liquid residue was slowly poured over 600 ml of ice. Neutralization (K₂CO₃) caused precipitation of an immiscible layer which was steam distilled and extracted with CH₂Cl₂. Evaporation of solvent *in vacuo* afforded 84.6 g of liquid which upon distillation gave 48.7 g (50%) of 6 [bp 90–93° (42 mm), n²⁴_D 1.5006 (lit.⁵ bp 174–175°)] and 30.3 g (29%) of 7, bp 113° (16 mm).

4-Methoxy-3-fluoro-2,6-lutidine (8). In a stainless-steel bomb was placed 40 g (0.25 mol) of 6 in 50 ml of MeOH and 100 ml of 2.6 N NaOCH₃-MeOH. After heating for 7 hr at 130°, the contents of the bomb were poured into 200 ml of H₂O. Extraction with CH₂Cl₂ afforded 37.7 g of liquid shown by nmr to be 92% 8 and 8% starting material 6. The product was used without purification since in the next step the starting material 6 is used up.

4-Hydroxy-3-fluoro-2,6-lutidine (9). In a stainless-steel bomb was placed 28 g of 8 and 150 ml of 5 N NaOCH₃-MeOH and the bomb was heated at 190° for 17 hr. The contents of the bomb were poured into 200 ml of H₂O and 100 ml of MeOH. The solution was neutralized (concentrated H₂SO₄) and the solvent removed *in vacuo* leaving a solid residue which was triturated with 400 ml of boiling MeOH. The filtrate yielded 25 g (98%) of 9, mp 248° dec. Sublimation [125° (0.2 mm)] gave pure product, mp 259° dec. *Anal.* (C₇H₈FNO) C, H, N.

3-Chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10). Into a solution of 10 g of 9, dissolved in 50 ml of H₂O and 25 ml of 5 N HCl, was bubbled Cl₂ gas with precipitation of product. The reaction mixture was neutralized (K₂CO₃) and the product 10 was filtered and washed with H₂O and Me₂CO, 4.2 g (34%). Sublimation [150° (0.2 mm)] gave pure product, mp >360°. *Anal.* (C₇H₈ClFNO) C, H, N.

3-Bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11). To 10 g of 9 dissolved in 75 ml of glacial AcOH was added 11.7 g of Br₂ dissolved in 20 ml of glacial AcOH. After stirring 2 hr, the product was filtered and washed with H₂O and Me₂CO: 6.1 g (39%), mp 270° dec. Recrystallization (DMF) gave pure 11, mp 284–286° dec. *Anal.* (C₇H₈BrFNO) C, H, N.

References

- (1) G. T. Stevenson, U. S. Patent 3,206,358 (1965).
- (2) R. H. Rigterink, U. S. Patent 3,246,001 (1966).
- (3) M. Conrad and M. Guthzeit, *Chem. Ber.*, 20, 154 (1887).
- (4) E. Ochiai and M. Fujimoto, *Chem. Pharm. Bull.*, 2, 131 (1954).
- (5) Z. Talik, T. Talik, and A. Puszyński, *Rocz. Chem.*, 39, 601 (1965); *Chem. Abstr.*, 63, 16298 (1965).
- (6) M. Bellas and H. Suschitzky, *J. Chem. Soc.*, 2096 (1965).